Docket No.: 09859/0203521-US0

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claim 1 (currently amended): A fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof represented by Formula (I):

-{ wherein R¹ represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; n represents an integer of 0 to 3; X¹ and X² may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; and formula (II):

(II)

represents formula (III):

-{ wherein X--Y--Z represents R²C=CR³-NR⁴ (wherein R², R³ and R⁴ may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or

unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group), R²C=N-NR⁴ (wherein R² and R⁴ have the same meanings as defined above, respectively), R⁴N-CR³=CR² (wherein R², R³ and R⁴ have the same meanings as defined above, respectively), or R⁴N-N=CR² (wherein R² and R⁴ have the same meanings as defined above, respectively)— or formula (IV):

-{ wherein Xa--Ya--Za represents R²HC-NR³-CHR⁴ (wherein R², R³ and R⁴ have the same meanings as defined above, respectively), R²HC-NR³-NH (wherein R² and R³ have the same meanings as defined above, respectively), or NH-NR³-CHR⁴ (wherein R³ and R⁴ have the same meanings as defined above, respectively)}.

Claim 2 (currently amended): The fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R¹ is substituted or unsubstituted lower alkyl.

Claim 3 (currently amended): The fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R³ is substituted or unsubstituted aryl, or substituted or unsubstituted lower alkyl.

Claim 4 (currently amended): The fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein X^1 is substituted or unsubstituted aralkyl and X^2 is a hydrogen atom.

Application No. 10/554,254 Docket No.: 09859/0203521-US0

Claim 5 (currently amended): A Pharmaceutical composition comprising the fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

Claims 6-13 (canceled).

Claim 14 (currently amended): A method for treating diabetes, which comprises administering an effective amount of the fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1.

Claim 15 (currently amended): A method for preventing and/or treating diabetic complications, which comprises administering an effective amount of the fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1.

Claim 16 (currently amended): A method for lowering blood glucose levels, which comprises administering an effective amount of the fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1.

Claim 17 (currently amended): A method for stimulating secretion of insulin, which comprises administering an effective amount of the fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof according to claim 1.

Claim 18 (new): A compound represented by the formula selected from the group consisting of the following Formulas (1) to (10):

or a pharmaceutically acceptable salt thereof.

Application No. 10/554,254 Docket No.: 09859/0203521-US0

Claim 19 (new): A method for treating diabetic complications, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 18.

Claim 20 (new): A method for lowering blood glucose levels, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 18.

Claim 21 (new): A method for stimulating secretion of insulin, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 18.